RxDoctor Payments Data

Jaskaran Bedi, MD

Internal Medicine · The Villages, FLNPI 1306831896

Payments from drug & device makers

$7,152in general payments, 2019–2025

Across 244 payments — averaging $29.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • GSK$1K
  • Amgen$479
  • Ironwood Pharmaceuticals, Inc$427
  • Bayer$414
  • Phathom Pharmaceuticals, Inc.$312
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,152100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,152 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$568,057
Medicare patients
563
Services billed
12,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin83$125,084
OzempicSemaglutide38$56,076
FarxigaDapagliflozin Propanediol44$52,055
XareltoRivaroxaban40$48,694
TradjentaLinagliptin26$39,082
EliquisApixaban31$36,459
MounjaroTirzepatide33$35,716
TrulicityDulaglutide12$32,607
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$27,618
JanuviaSitagliptin Phosphate21$26,707
GemtesaVibegron14$11,967
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$8,266
Levothyroxine Sodium373$4,186
Atorvastatin Calcium411$3,903
Rosuvastatin Calcium253$3,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$145$164,167109 claims
Lilly USA, LLCMounjaro, Trulicity$260$68,32345 claims
Novo NordiskOzempic$177$56,07638 claims
AstraZenecaFarxiga$225$52,05544 claims
Johnson & JohnsonXarelto$1,230$48,69440 claims
PfizerEliquis$259$36,45931 claims
GSKTrelegy Ellipta$1,156$27,61822 claims
MerckJanuvia$130$26,70721 claims
Sumitomo Pharma America, Inc.Gemtesa$63$11,96714 claims
AbbVieSynthroid$38$1,87756 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →